Bicyclic heteroaromatic derivatives for the treatment of immune and inflammatory disorders

A compound of formula (1):

• 10
• wherein:
• q is zero or the integer 1, 2 or 3;
• R which when present may be attached to any available carbon or nitrogen atom of the bicyclic heteroaromatic ring of formula (1) is an atom or group -L3(Alk3)wL4(R8)u in which L3 and L4 which may be the same or different is each a covalent bond or a linker atom or group, w is zero or the integer 1, u is the integer 1, 2 or 3, Alk3 is an optionally substituted aliphatic or heteroaliphatic chain and R8 is a hydrogen or halogen atom (or a group selected from alkyl, —OR9 [where R9 is a hydrogen atom or an optionally substituted alkyl group], —SR9, —NR9R10, [where R10 is as just defined for R9 and may be the same or different]. —NO2, —CN, —CO2R9, —OCO2R9, —CONR9R10, —OCONR9R10, —CSNR9R10, —COR9, —OCOR9, —N(R9)COR10, —N(R9)CSR10, —SO2N(R9)(R10), —N(R9)SO2R10, —N(R9)CON(R10)(R11), [where R11 is a hydrogen atom or an optionally substituted alkyl group], —N(R9)CSN(R10)(R11), —N(R9)SO2N(R10)(R11) or an optionally substituted cycloaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group provided that when w is zero and each of L3 and L4 is a covalent bond then u is the integer 1;
• or
• when q is the integer 2 or 3 and two R groups are attached to adjacent carbon atoms of the heteroaromatic ring of formula (1) these may be joined together with the heteroaromatic ring carbon atoms to form an optionally substituted cycloaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group;
• X is an O atom or a S(O)m atom or group in which m is zero or the integer 1 or 2 or an NR group;
• Y is a N atom or a CR1a group in which R1a is a group R or a group R1;
• R1 which may be on any available carbon atom of the bicyclic heteroaromatic ring of formula (1) is a hydrogen atom or a group -Alk1L1CyAlk2L2D in which Alk1 is an optionally substituted C1-3alkyl group, Alk2 is an optionally substituted aliphatic or cycloaliphatic group, L1 is a —CON(R5)—, —N(R5)CO—, —SO2N(R5)— or —N(R5)SO2— group in which R5 is a hydrogen atom or an optionally substituted aliphatic, heteroaliphatic, cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, heteropolycycloaliphatic, aromatic, or heteroaromatic group, L2 is a covalent bond or an —O— atom or —S(O)n— atom or group in which n is zero or the integer 1 or 2 or —N(R7)— group in which R7 is a hydrogen atom or an optionally substituted aliphatic, heteroaliphatic, cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, neteropolycycloaliphatic, aromatic, or heteroaromatic group, D is an optionally substituted aliphatic, heteroaliphatic, cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, heteropolycycloaliphatic, aromatic, or heteroaromatic group and Cy is an optionally substituted heterocycloaliphatic ring of formula (A) or (B):
• 11
• in which
• a indicates the point of attachment of any available ring carbon in the ring Cy to the group L1, b indicates the point of attachment to Alk2, s and t which may be the same or different is each zero or the integer 1 or 2, provided that s+t is the integer 1, 2, 3 or 4, R6 is an optionally substituted alkyl group and X is a pharmaceutically acceptable counterion;
• provided that at least one but not both of R1 and R1a is the group -Alk1L1CyAlk2L2D;
• and the salts, solvates, hydrates, N-oxides thereof.